Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Mon, 18th Oct 2021 15:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Mind Gym PLC - London-based training and management development company - Expects revenue of GBP24.1 million in the six months ended September 30, up 66% year-on-year from GBP14.5 million. Revenue remained slightly above the GBP23.9 million reported in the comparative pre-Covid period, two years earlier. Says 82% of income was "digitally enabled". Continues to invest in its technological capacities ahead of the planned launches of its new digital products. Expects to release its interim results on December 3.

----------

Dispersion Holdings PLC - decentralised finance investor using blockchain and cryptocurrencies to remove financial intermediaries from transactions - Acquires Accru Finance Ltd for GBP8.8 million, to be paid via the issue of 250 million new company shares. Accru's sellers will then hold a 29% stake in Dispersion. The company says Accru plans to launch: "the first internationally-regulated and insured platform for the trading and yield farming of cryptocurrencies." Expects to approve the deal at the company's general meeting next Tuesday.

----------

IXICO PLC- AI data analytics company based in London - Reports revenue of GBP9.2 million in the year ended September 30, down 3.2% from GBP9.5 million a year prior but 5.7% above market expectations of GBP8.7 million. Expects earnings before interest, tax, depreciation and amortisation of GBP1.2 million, in line with market expectations but slightly below the GBP1.3 million taken a year earlier. Notes that this reflects the GBP7.1 million adverse impact of lost revenue from the end of its Huntington's Disease trial in March. Expects lower profitability in financial 2022 as the company invests in long-term sustained growth.

----------

7digital Group PLC - London-based music licensing provider - Secures GBP1 million expansion to revolving credit facility with Investec Bank. Brings total facility with Investec up to GBP2 million total. Says the enlarged facility matures in September 2023, in keeping with the original terms agreed with the bank in September 2020. Issues 5.4 million warrants with an excise price of 0.55 pence and a lifespan of 36 months, as an arrangement fee to Investec.

----------

Artisanal Spirits Co PLC - Edinburgh, Scotland-based owner of the Scotch Malt Whisky Society - Signs 10-year lease for a new supply chain facility in Uddingston, Scotland. Says the 37,000 square foot facility will provide the company with greater control over its supply chain, in order to improve its margins over time. It includes warehousing, production and office space, with equipment due to be installed in early 2022. The facility is scheduled to become fully operation in the second half of 2022, the company adds.

----------

Destiny Pharma PLC - Brighton, England-based clinical stage biotechnology company focused on life threatening infections - Says US hospital-based study supports potential of XF-73 nasal product to reduce intensive care unit infections. The phase 4 study includes 300,000 patients and shows 23% of all ICU infections are caused by the staphylococcus aureus bacteria. Proposes its XF-73 product as an alternative to mupirocin for these infections. Notes current regulatory talks concerning phase 3 studies to obtain marketing approval for XF-73 in the US and Europe.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Sees first subject treated at Oxford Eye Hospital in a Phase 2a RP trial of its therapeutic candidate for retinitis pigmentosa, a degenerative eye disease. The study uses 2 million cell doses on subjects with some remaining vision, despite having advanced retinitis pigmentosa. Appoints Catherine Isted as chief financial officer and executive director. Notes the departure of non-executive director Chris Evans as he approaches non-independent status after nine years on the board.

----------

Hemogenyx Pharmaceuticals PLC - London-based developer of drugs for blood diseases - Leases custom laboratory at the Mink Building in New York from The Janus Property Co. Says the new laboratory is close to Columbia University and City College, possibly easing future collaboration. The 10,000 square foot laboratory includes two purpose built clean rooms. The company says the new space will be used to pursue commercialisation of its major cell therapy product candidates by manufacturing cells in-house, starting with its HEMO-CAR-T treatment for acute myeloid leukemia.

----------

Corcel PLC - London-based mineral explorer and developer with interests in battery metals and flexible energy generation & storage - Acquires Wo Wo Gap Nickel-Cobalt project in Papua New Guinea. Says it acquired the project as it reached a share purchase agreement with Resource Mining Corp Ltd to acquire the entire issued share capital of the project's owner Niugini Nickel Pty Ltd. "Near term priorities at Wo Wo gap will include resource updates, exploring synergies with our Mambare project, and the early securing of long term shipping and offtake arrangements," says Corcel's executive chair James Parsons.

----------

IGas Energy PLC - Lincoln-based oil and gas producer - Agrees head of terms with Iona Capital Ltd to develop utility scale solar farms in the UK. Initially plans to develop a 25 to 40 megawatt solar farm in southern England, the first of several similar projects. "IGas will contribute its planning and infrastructure expertise, whilst Iona will provide non-recourse project finance. During the development phase, costs will be shared and throughout the project lifecycle, IGas and Iona will each own 50% of the project," the company says.

----------

Gem Diamonds Ltd - London-based miner - Recovers high quality Type 2, 245 carat Type 2 and 102 carat white diamonds. Says it uncovered the stones from the Letseng mine in Lesotho, "the highest dollar per carat kimberlite diamond mine in the world".

----------

Ethernity Networks Ltd - Networking and security solutions provider based in Israel - Secures USD3 million order with Chinese broadband network OEM. Says the order is for customised FPGA system-on-chip processors and covers 2022 and 2023. Expecs further orders thereafter. Under the terms of the agreement, the company will supply OEM with its system-on-chip devices with support for four Gigabit Passive Optical Networking Optical Line Termination ports and four 10Gbps XGS-PON OLT MAC ports by the second quarter of 2022. These products support OEM's 5G and fibre access developments.

----------

Castillo Copper Ltd - Australia and Zambia-focused base metal copper exploration company - Begins drilling at its Arya Copper Prospect in the Mount Isa region of Queensland, Australia. Says drilling follows a significant logistical effort to prepare the drill-pads, heli-lift and other equipment at the site. Plans to drill five initial holes as "proof of concept" at the Arya site and expects to expand the campaign to fully test the area. Focuses drilling on targets identified by BHP in the 1990s, including EG01, EG02 and EG101,2. Notes large a potential 130 metre-thick sulphide bedrock conductor at the EG01 target. Says initial observations are encouraging. Notes concurrent rock chip sampling campaign to extend the known surface anomaly to the south.

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Wins GBP230,000 contract to provide specialist deep cleaning services for a rail sector client. The contract runs for 25-weeks through to the end of March 2022, the company adds. "Securing this contract highlights the quality and depth of work being provided by the specialist teams within the group and continues to strengthen our presence in the rail sector," says Chief Executive Shaun Doak.

----------

Home REIT PLC - London-based real estate investment trust - Spends GBP166.4 million on property pipeline. Acquires 23 portfolios including 366 properties across England and Wales. Funds the purchases with proceeds from its oversubscribed GBP350 million equity issue in September. Says its total property pipeline totals GBP400 million.

----------

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2013 08:31

ReNeuron Group wins grants for stem cell therapy development

ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for

Read more
29 Jan 2013 10:29

ReNeuron Group edges further in stem cell therapy research for stroke patients

ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke

Read more
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.